Načítá se...

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors

In Chronic Myeloid Leukemia (CML), successful treatment requires accurate molecular monitoring to evaluate disease response and provide timely interventions for patients failing to achieve the desired outcomes. We wanted to determine whether measuring BCR-ABL1 mRNA doubling-times (DTs) could disting...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Oncol
Hlavní autoři: Pennisi, Maria Stella, Stella, Stefania, Vitale, Silvia Rita, Puma, Adriana, Di Gregorio, Sandra, Romano, Chiara, Tirrò, Elena, Massimino, Michele, Antolino, Agostino, Siragusa, Sergio, Mannina, Donato, Impera, Stefana, Musolino, Caterina, Mineo, Giuseppe, Martino, Bruno, Zammit, Valentina, Di Raimondo, Francesco, Manzella, Livia, Stagno, Fabio, Vigneri, Paolo
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2019
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6700306/
https://ncbi.nlm.nih.gov/pubmed/31456947
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00764
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!